News | Proton Therapy | November 21, 2018

Ohio State University to Open Region's First Proton Therapy Facility

New 55,000-square-foot proton therapy facility scheduled to open for adult and pediatric patients in 2021

Ohio State University to Open Region’s First Proton Therapy Facility

Image courtesy of The Ohio State University James Comprehensive Cancer Center

November 21, 2018 — The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research Institute are collaborating with Nationwide Children’s Hospital to bring the first proton therapy treatment facility to central Ohio. This will offer state-of-the-art radiation oncology treatment for adult and pediatric cancer patients in one place.

The proton center will be located at the new 340,000 square-foot outpatient facility planned for Ohio State’s west campus. The proton therapy portion is expected to utilize 55,000 square feet and cost approximately $100 million. Nationwide Children’s has committed to up to 50 percent of the expected proton center project cost.

“This is a significant advancement for our patients and their families,” said Ohio State President Michael V. Drake. “As part of our nationally renowned Wexner Medical Center, comprehensive cancer center and health sciences campus, this facility will spark leading-edge research, inspire new academic partnerships and drive innovative solutions to combat this ubiquitous and devastating disease.”

Proton therapy is an advanced type of radiation treatment that uses protons (positively charged particles) instead of X-rays to kill cancer cells. A machine delivers a high-energy proton beam painlessly through the skin from outside the body.

“As central and southern Ohio’s only National Cancer Institute-designated comprehensive cancer center, it’s our duty to bring advanced, evidence-based treatment options like proton therapy to the region for benefit of patients in need of this type of subspecialized care,” said William Farrar, M.D., interim chief executive officer of The James.

Proton therapy can be used alone or in combination with other therapies to treat several localized cancers, including prostate, brain, head and neck, lung, spine and gastrointestinal in adults, as well as brain cancer, lymphoma, retinoblastomas and sarcomas in children.

“Having a proton therapy treatment facility in Columbus will enable more pediatric patients from central Ohio to receive all of their cancer treatment closer to home,” said Timothy Cripe, M.D., Ph.D., division chief of hematology, oncology, bone marrow transplantation at Nationwide Children’s. “As a national leader in pediatric research and quality improvement, we can establish clinical trials that focus on how proton therapy affects specific types of pediatric cancer. Furthermore, because we always seek to provide best outcomes for all our patients, we’ll examine quality improvement best practices for administration and safety.”

Children are vulnerable to the long-term side effects of radiation, including growth abnormalities, cognitive impairment, heart damage and other complications such as radiation-induced secondary cancers later in life. The American Society of Clinical Oncology reports proton therapy may deliver up to 60 percent less radiation to healthy surrounding tissue and a higher dose to the tumor itself. This makes it an important treatment option for certain pediatric cancers.

“It’s important to note that traditional targeted radiation therapy techniques are still highly effective for many solid tumors, but proton therapy is an exciting new option for localized tumors. It allows us to deliver the highest concentration of treatment directly to cancerous tissue, while sparing delicate surrounding tissue that – if damaged as a side effect of cancer treatment – could result in quality-of-life impacting toxicity,” said Arnab Chakravarti, M.D., chair of radiation oncology at The James.

The new proton therapy center, managed by The James radiation oncology experts, is expected to open in 2021.

For more information: www.cancer.osu.edu

Related Content

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...
A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beam will ablate for a noninvasive pulmonary vein isolation procedure. Varian acquires, buys, purchases Cyberheart.

A CyberHeart cardiac ablation radiotherapy treatment plan showing where the radiation beams will ablate for a noninvasive pulmonary vein isolation procedure to treat an arrhythmia.

Feature | Radiation Therapy | May 10, 2019
May 10, 2019 — Radiation oncology vendor Varian announced it acquired the start-up company CyberHeart, which has deve